Novartis to pay $72.5 million in US false claim settlement on off-label use of Tobi
This article was originally published in Scrip
Executive Summary
Novartis has agreed to pay $72.5 million to settle allegations that it submitted false claims to federal healthcare programmes for off-label uses of its cystic fibrosis drug Tobi (tobramycin solution for inhalation), the US Justice Department said.